Reports

Hewlett Packard Enterprise delivered strong fiscal Q1 2026 results with revenue growing 18% year-over-year to $9.30B. Networking revenue surged more than 150% driven by the Juniper integration, while operating profitability improved with higher margins in the Cloud & AI segment.

• Revenue increased 18% year-over-year to $9.30B driven primarily by networking growth.
• Networking revenue surged 151.5% year-over-year following Juniper integration.

Casey's reported modest revenue growth but strong profitability improvements in Q3 FY2026. Higher inside margins and stronger fuel margins drove a significant increase in net income and EPS compared to the prior year.

• Quarterly revenue reached $3916132000, slightly higher year over year.
• Net income increased to $130073000 with diluted EPS of $3.49.

Vail Resorts faced significant headwinds in Q2 2026 due to historically low snowfall and warm temperatures in the Rockies, leading to a 13% decline in visitation. Despite these challenges, the company's advance commitment strategy and cost management efforts mitigated the impact, though the company ultimately lowered its full-year fiscal 2026 guidance.

• Net income attributable to Vail Resorts decreased to $210.0 million from $244.4 million in the prior year.
• Resort Reported EBITDA fell 8.3% to $421.3 million, driven by weather-related visitation declines.

BETA Technologies exceeded performance guidance in Q4 2025, driven by increased product deliveries and engineering services. While the company reported a net loss of $150 million for the quarter, it ended the year with a robust cash balance of $1.7 billion and a commercial backlog of 891 aircraft valued at approximately $3.5 billion.

• Quarterly revenue grew 151% year-over-year to $11.13 million, driven by motor deliveries and engineering services.
• Successfully completed an IPO and private financings, resulting in a cash balance of $1.71 billion at year-end.

ZIM faced a challenging fourth quarter with revenues dropping 32% year-over-year to $1.48 billion, primarily due to lower freight rates and carried volumes. Despite the downturn, the company maintained a strong cash position and declared a Q4 dividend of $106 million, while announcing a pending merger with Hapag-Lloyd at $35.00 per share.

• Net income for Q4 2025 was $38 million, a sharp decrease from $563 million in Q4 2024.
• Average freight rate per TEU fell 29% year-over-year to $1,333 in the fourth quarter.

Korn Ferry achieved record third-quarter fee revenue of $717.4 million, driven by growth across all business segments, particularly Executive Search. Net income and Adjusted EBITDA both saw double-digit and high single-digit growth respectively, while the company maintained stable margins despite increased compensation expenses.

• Fee revenue grew 7% year-over-year to $717.4 million, with Executive Search leading at 13% growth.
• Net income attributable to Korn Ferry rose 12% to $65.3 million, with a margin of 9.1%.

GBTG delivered strong Q4 2025 results with revenue growth driven by higher business travel demand and the CWT acquisition. Net income turned positive while Adjusted EBITDA increased year-over-year.

• Revenue increased 34% year-over-year to 792000000 driven by travel demand and the CWT acquisition.
• Net income reached 83000000 compared with a 14000000 loss in the prior year quarter.

Dianthus Therapeutics reported minimal Q4 2025 revenue while operating expenses increased significantly due to higher research and development activity supporting the advancement of claseprubart and DNTH212 programs, resulting in a larger quarterly net loss.

• Total revenue declined to 284000 compared with 1325000 in the prior year quarter.
• Net loss widened to 64432000 from 28438000 year-over-year.

Nayax delivered a robust fourth quarter with revenue increasing 34% year-over-year to $119.5 million. The company achieved a net income of $13.2 million, a substantial improvement from $1.6 million in the prior year, driven by strong demand for POS devices (particularly in EV charging) and improved processing margins. The company also successfully raised $173.9 million through a note and warrant offering in December.

• Q4 revenue grew 34.3% YoY to $119.5 million, with organic growth at 30%.
• Net income for the quarter rose to $13.2 million compared to $1.6 million in Q4 2024.

Voyager reported record Q4 net sales led by strong Defense and National Security growth, while Space Solutions declined due to the planned NASA services contract wind-down. The company exited 2025 with record backlog and strong liquidity, but still posted a sizable quarterly net loss and negative free cash flow.

• Q4 net sales reached a record $46.65 million, up 23.7% year over year.
• Defense and National Security revenue grew 62.5% year over year to $35.71 million.

SharpLink Gaming reported strong Q4 2025 staking revenue growth driven by its Ethereum treasury strategy, though GAAP net results were significantly impacted by unrealized losses related to ETH price volatility. The company continued expanding its ETH treasury operations and institutional ownership base.

• Q4 staking revenue reached 15300000 reflecting strong growth in treasury yield operations.
• GAAP net loss for 2025 totaled 734600000 primarily driven by unrealized crypto asset losses.

Yalla reported Q4 2025 revenue of 83860924 and net income of 34533531, maintaining high profitability with a net margin above 40%. The company continued to grow its user base, with monthly active users increasing year over year and strong engagement supporting monetization.

• Revenue reached 83860924 in the fourth quarter of 2025.
• Net income totaled 34533531 with strong profitability and a 41.2% net margin.

ARS Pharmaceuticals reported Q4 2025 revenue of $28.1 million, driven by the U.S. commercial launch of neffy. While the company is seeing strong adoption with over 22,500 prescribing HCPs, it recorded a net loss of $41.3 million for the quarter due to significant investments in direct-to-consumer marketing and sales force expansion.

• neffy generated $20.3 million in U.S. net product revenue during the fourth quarter.
• More than 22,500 healthcare providers have prescribed neffy to date, with a 50% repeat prescriber rate.

Heritage Insurance reported strong Q4 2025 profitability as net income more than tripled year-over-year due to significantly lower loss ratios and improved underwriting efficiency, while revenue grew modestly.

• Net income surged more than 228% year-over-year to $66675000 driven by improved underwriting performance.
• Combined ratio improved significantly to 62.0% from 89.7% last year, reflecting lower losses and expenses.

Kronos Worldwide faced a challenging fourth quarter in 2025, reporting a net loss of $82.8 million. The results were primarily impacted by higher unabsorbed fixed production costs due to significant production curtailments (operating at only 55% capacity) and lower average TiO2 selling prices, despite a slight increase in sales volumes.

• Net loss widened to $82.8 million in Q4 2025 compared to a $13.2 million loss in Q4 2024.
• Production facilities operated at only 55% capacity in Q4 2025 to manage inventory, resulting in $54 million of unabsorbed fixed costs.

enGene reported a higher net loss in Q1 2026 as operating expenses increased to support the LEGEND clinical trial and preparation for a planned BLA submission for detalimogene. The company maintains a strong balance sheet with over $312 million in cash and marketable securities expected to fund operations into the second half of 2028.

• Net loss increased to 29752000 from 24616000 in the prior year quarter.
• Total operating expenses rose to 31185000 driven by higher R&D and administrative costs.

Yext achieved a significant milestone in Q4 2026 by delivering GAAP net income of $4.2 million compared to a loss in the prior year. While revenue saw a slight year-over-year decline, the company demonstrated strong operational efficiency with an Adjusted EBITDA margin of 26% and robust free cash flow generation.

• Achieved Q4 GAAP net income of $4.2 million, a significant turnaround from the $7.3 million loss in Q4 2025.
• Adjusted EBITDA reached $29.0 million for the quarter, representing a 26% margin.

Design Therapeutics reported a net loss of $16.0 million for the fourth quarter of 2025 as it continues to advance its GeneTAC clinical portfolio. The company maintains a strong liquidity position with $219.8 million in cash and securities, providing an operating runway into 2029.

• Ongoing Phase 1/2 MAD trial for DT-216P2 in Friedreich Ataxia with data update expected in H2 2026.
• Phase 2 biomarker trial for DT-168 in FECD is ongoing with data anticipated in H2 2026.

Zevra Therapeutics achieved significant revenue growth in Q4 2025, driven by the strong commercial launch of MIPLYFFA for Niemann-Pick disease type C. The company transitioned to profitability for the quarter and full year, bolstered by the sale of a Priority Review Voucher and disciplined expense management.

• Q4 net revenue grew 31% quarter-over-quarter to $34.1 million.
• MIPLYFFA generated $26.4 million in Q4 net revenue, representing the primary growth driver.

Greenlight Re achieved a significant turnaround in Q4 2025, reporting net income of $49.3 million compared to a loss in the prior year. The company saw strong underwriting performance with a combined ratio of 92.1% and a substantial increase in investment income from its Solasglas portfolio.

• Net income reached $49.3 million, or $1.44 per diluted share, reversing a $27.4 million loss in Q4 2024.
• The combined ratio improved significantly to 92.1% from 112.1% in the prior-year period.

ACCO Brands reported lower Q4 2025 sales due to softer demand across core categories, though cost savings and pricing actions helped maintain profitability with modest net income growth year-over-year.

• Net sales declined 4.3% year-over-year to 428800000 due to softer global demand.
• Operating income was 40000000 compared with 42000000 in the prior year quarter.

FuelCell Energy reported strong Q1 FY2026 revenue growth driven primarily by product module deliveries under long-term service agreements, though the company continued to report operating losses and negative gross margins.

• Revenue increased 61% year-over-year to 30531000 driven mainly by product revenue.
• Net loss narrowed to 26051000 compared with 32386000 in the prior year quarter.

3D Systems reported Q4 revenue of $106.3 million, exceeding guidance with 16% sequential growth. While the company faced a net loss, it significantly improved its Adjusted EBITDA and reduced operating expenses through cost-saving initiatives, while also strengthening its balance sheet by retiring debt.

• Q4 revenue of $106.3 million grew 16% sequentially, driven by strong printer sales and materials consumption.
• Healthcare Solutions segment revenue increased 25% year-over-year to $50.5 million.

REPAY reported flat year-over-year revenue for Q4 2025, heavily impacted by the lapping of 2024 political media spending. However, the company saw strong normalized growth of 10%. The quarter was marked by a significant net loss of $148.3 million, primarily due to a $138.5 million non-cash goodwill impairment charge in the Consumer Payments segment.

• Normalized revenue and gross profit growth increased by 10% and 9% respectively, excluding cyclical political media spending.
• Net loss of $148.3 million was driven by a $138.5 million non-cash goodwill impairment loss in the Consumer Payments segment.

RideNow Group saw a 4.7% decrease in total revenue to $256.9 million in Q4 2025, but achieved a 5.0% increase in gross profit. The company significantly reduced its net loss to $6.4 million compared to $56.4 million in the prior year, largely due to lower impairment charges. Adjusted EBITDA saw a substantial increase to $9.7 million, and the company successfully exited its vehicle transportation services business at year-end.

• Powersports gross profit increased 10.1% year-over-year to $70.7 million in Q4.
• Same-store sales revenue grew 6.3%, driven by a 7.7% increase in same-store unit sales.

Amplify Energy reported Q4 revenue of 56554000 and net income of 64411000 primarily due to gains from asset sales. Operationally, the company generated 21460000 of Adjusted EBITDA and modest free cash flow while average production declined sequentially following divestitures and operational adjustments.

• Q4 revenue totaled 56554000 driven primarily by oil and natural gas sales.
• Net income reached 64411000 largely due to gains from asset divestitures.

Coherus reported higher Q4 revenue driven by LOQTORZI growth, but operating losses remained large as R&D spending increased. The company continues transitioning toward an oncology-focused pipeline while reducing debt and maintaining a sizable cash position.

• Q4 revenue rose year over year driven primarily by LOQTORZI sales growth.
• Operating loss remained significant due to continued R&D investment.

Voyager Therapeutics reported a significant increase in quarterly collaboration revenue and maintained a strong cash position of $201.7 million, which is expected to fund operations into 2028. While the company realized a net loss for the quarter, it was narrower than the previous year's Q4, and the company is preparing for multiple clinical entries in the second half of 2026.

• Collaboration revenue for Q4 increased to $15.3 million, up from $6.3 million in the prior year period, driven by the Neurocrine agreement.
• Cash runway is projected to extend into 2028, supported by $201.7 million in cash, cash equivalents, and marketable securities.

Cartesian Therapeutics reported approximately $947000 in revenue in Q4 2025, derived primarily from grant funding and collaboration revenue. The company posted an estimated net loss of about $36098000 for the quarter with EPS of -1.39, reflecting continued investment in clinical development including the Phase 3 AURORA trial.

• Q4 revenue was approximately 947000 based primarily on grant funding and collaboration income.
• EPS for the quarter was -1.39 as the company continued heavy clinical investment.

Editas Medicine reported lower collaboration revenue in Q4 2025 while significantly reducing operating expenses after discontinuing the reni-cel program, resulting in a substantially smaller net loss year-over-year. The company continues advancing its lead in vivo candidate EDIT-401 and maintains a strong cash runway into 2027.

• Collaboration and other R&D revenue declined to 24741000 from 30604000 year-over-year.
• Net loss improved significantly to 5620000 compared with 45395000 in the prior year quarter.

LifeMD generated $46.87M in Q4 revenue, up 4% year-over-year, while gross margin expanded significantly to 87%. The company reported net income of $19.94M largely driven by discontinued operations related to the WorkSimpli sale, while the core telehealth business continued scaling with subscriber growth.

• Revenue grew 4% year-over-year to $46868484.
• Gross margin expanded to 87% reflecting improved revenue mix.

Corbus Pharmaceuticals reported a net loss of $20.6 million for Q4 2025 as it ramped up clinical development for its oncology and obesity pipelines. The company successfully extended its cash runway into 2028 following a $75 million public offering and reported positive early-stage data for its lead candidates CRB-701 and CRB-913.

• Reported positive Phase 1/2 data for CRB-701 in HNSCC and cervical cancer with unconfirmed ORRs of 47.6% and 37.5% respectively.
• CRB-913 Phase 1a data demonstrated 2.9% placebo-adjusted weight loss at 14 days with a favorable GI safety profile.

MacroGenics generated significant collaboration and manufacturing revenue in Q4 2025, leading to positive operating income and net income following losses earlier in the year. The quarter reflected milestone and collaboration payments as well as increased contract manufacturing activity.

• Q4 revenue was approximately 41227000 calculated from full-year results after strong earlier collaboration revenue.
• The company generated positive operating income and net income in the fourth quarter.

Eltek reported a revenue increase of 23% in Q4 2025 to $13.2 million, but faced a net loss of $0.3 million due to operational challenges from manufacturing upgrades and significant currency headwinds. The company is undergoing a strategic transformation, investing in new plating lines and infrastructure to target high-growth defense and medical sectors.

• Q4 revenue grew to $13.2 million, up from $10.8 million in the prior year period.
• The company recorded a net loss of $0.3 million in Q4 compared to a small profit in Q4 2024.

Myomo reported a 6% decrease in Q4 revenue to $11.4 million, primarily due to lower unit volume and average selling prices. Despite the quarterly decline, the company achieved record full-year revenue and is shifting its strategy toward recurring patient sources and O&P channels to improve margins and reduce customer acquisition costs in 2026.

• Q4 revenue of $11.4 million decreased 6% year-over-year, though full-year revenue grew 26% to $40.9 million.
• Recurring patient sources accounted for 42% of Q4 revenue, up significantly from 26% in the prior year quarter.